Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aviron raises $64.2 million

AVIR, a developer of vaccines, raised $49.5 million in a follow-on offering of

Read the full 135 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE